Skip to content
Screener

Cytek Biosciences, Inc. CTKB Total Cost of Revenue

Total Cost of Revenue at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$2.67B-7.2%
Danaher logo
DanaherDHR
$2.65B+10.0%
Revvity logo
RevvityRVTY
$312.82M-4.5%
Agilent Technologies logo
Agilent TechnologiesA
$845M+5.4%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$49.65M+10.0%
Bruker logo
BrukerBRKR
$422.5M-3.9%

Segments

By product

See full
Service$6.92M+1.5%

Other financials

Income statement

See full
Revenue$48.1M+5.6%
Gross profit$28.3M+18.7%
Operating income-$11.4M-7.3%
Net income-$12.2M-118%
EPS (diluted)-$0.09-125%

Balance sheet

See full
Cash & equivalents$73.8M-2.2%
Total debt$17.0M-6.6%
Total equity$322.0M-14.7%
Total assets$446.9M-9.4%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+40.5%
Free cash flow-$849.0K+42.2%

Valuation

See full
Market cap$545.93M+25.6%
Enterprise value$489.11M+29.2%
P/S2.6×+0.4×

Profitability

See full
Gross margin53.2%-1.2pp
Operating margin-21.6%
Net margin-39%
FCF margin-5.8%-11.4pp

Returns & leverage

See full
Return on equity-23%
Debt / equity0.1×0.0×
Current ratio4.5×-0.7×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053496
(In thousands, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of sales:
Product12,88414,92128,80530,450
Service6,9166,81413,87612,585
Total cost of sales19,80021,73542,68143,035
Gross profit28,34023,86749,59444,024
Operating expenses:
Research and development9,7418,82619,34518,550
Sales and marketing13,17412,13424,82024,643

Item 1. Consolidated Financial Statements (Unaudited)

FAQ

What is Cytek Biosciences, Inc.'s total cost of revenue?
Cytek Biosciences, Inc. (CTKB) reported total cost of revenue of $19.8M in Q2 2026.
How has Cytek Biosciences, Inc.'s total cost of revenue changed year-over-year?
Cytek Biosciences, Inc.'s total cost of revenue decreased by 8.9% year-over-year, from $21.74M to $19.8M.
What is the long-term trend for Cytek Biosciences, Inc.'s total cost of revenue?
Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s total cost of revenue has grown at a 18.7% compound annual growth rate (CAGR), from $48.81M to $97.03M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Cytek Biosciences, Inc.'s total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude